Cargando…

Minimize the extent and morbidity of axillary dissection for node-positive breast cancer patients: implementation of axillary lymph node dissection based on breast lymphatics level

BACKGROUND: Breast cancer-related lymphedema (BCRL) is associated with extensive axillary dissection. Axillary lymph node dissection (ALND) based on breast lymphatics level (BLL) was proposed to minimize the surgical extent for node-positive breast cancer patients. METHODS: A total of 156 consecutiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Qianqian, Hou, Jinxuan, He, Yukun, Liao, Yiqian, Zheng, Lewei, Wu, Gaosong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7980601/
https://www.ncbi.nlm.nih.gov/pubmed/33740930
http://dx.doi.org/10.1186/s12885-021-08024-y
_version_ 1783667461182193664
author Yuan, Qianqian
Hou, Jinxuan
He, Yukun
Liao, Yiqian
Zheng, Lewei
Wu, Gaosong
author_facet Yuan, Qianqian
Hou, Jinxuan
He, Yukun
Liao, Yiqian
Zheng, Lewei
Wu, Gaosong
author_sort Yuan, Qianqian
collection PubMed
description BACKGROUND: Breast cancer-related lymphedema (BCRL) is associated with extensive axillary dissection. Axillary lymph node dissection (ALND) based on breast lymphatics level (BLL) was proposed to minimize the surgical extent for node-positive breast cancer patients. METHODS: A total of 156 consecutive sentinel lymph node-positive (SLN+) or clinically node-positive (cN+) patients underwent sentinel lymph node biopsy (SLNB) with indocyanine green and methylene blue (MB). The SLNs were injected with 0.1 ml MB before removal, and a standard ALND was subsequently performed. The nodes adjacent to the blue-stained axillary lymph nodes from the breast (bALNs) were sent for pathological examination separately by resecting serial tissue every 0.5 cm away from the marginal blue-stained bALNs. Then, a pilot study comparing ALND based on BLL and standard ALND was performed. RESULTS: BLL were successfully identified in 20 SLN+ (100%) and 134 cN+ (98.5%) patients. The median number of BLL was four, ranging from three to six. A horizontal line 1.0 cm away from the superior blue-stained bALN and a vertical line 1.0 cm away from the medial blue-stained bALN formed BLL II, III, and IV. All of the additional positive nodes were within 1.0 cm of the blue-stained bALNs. The minimized axillary dissection should resect upwards from the lowest BLL that contains the first confirmed negative blue-stained bALNs. In the pilot study, no patient developed axillary recurrence. CONCLUSION: The ALND surgical procedure based on BLL could minimize the surgical extent for pathological node-positive breast cancer patients and potentially reduce the BCRL rate. TRIAL REGISTRATION: ChiCTR1800014247. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08024-y.
format Online
Article
Text
id pubmed-7980601
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-79806012021-03-22 Minimize the extent and morbidity of axillary dissection for node-positive breast cancer patients: implementation of axillary lymph node dissection based on breast lymphatics level Yuan, Qianqian Hou, Jinxuan He, Yukun Liao, Yiqian Zheng, Lewei Wu, Gaosong BMC Cancer Research Article BACKGROUND: Breast cancer-related lymphedema (BCRL) is associated with extensive axillary dissection. Axillary lymph node dissection (ALND) based on breast lymphatics level (BLL) was proposed to minimize the surgical extent for node-positive breast cancer patients. METHODS: A total of 156 consecutive sentinel lymph node-positive (SLN+) or clinically node-positive (cN+) patients underwent sentinel lymph node biopsy (SLNB) with indocyanine green and methylene blue (MB). The SLNs were injected with 0.1 ml MB before removal, and a standard ALND was subsequently performed. The nodes adjacent to the blue-stained axillary lymph nodes from the breast (bALNs) were sent for pathological examination separately by resecting serial tissue every 0.5 cm away from the marginal blue-stained bALNs. Then, a pilot study comparing ALND based on BLL and standard ALND was performed. RESULTS: BLL were successfully identified in 20 SLN+ (100%) and 134 cN+ (98.5%) patients. The median number of BLL was four, ranging from three to six. A horizontal line 1.0 cm away from the superior blue-stained bALN and a vertical line 1.0 cm away from the medial blue-stained bALN formed BLL II, III, and IV. All of the additional positive nodes were within 1.0 cm of the blue-stained bALNs. The minimized axillary dissection should resect upwards from the lowest BLL that contains the first confirmed negative blue-stained bALNs. In the pilot study, no patient developed axillary recurrence. CONCLUSION: The ALND surgical procedure based on BLL could minimize the surgical extent for pathological node-positive breast cancer patients and potentially reduce the BCRL rate. TRIAL REGISTRATION: ChiCTR1800014247. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08024-y. BioMed Central 2021-03-19 /pmc/articles/PMC7980601/ /pubmed/33740930 http://dx.doi.org/10.1186/s12885-021-08024-y Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Yuan, Qianqian
Hou, Jinxuan
He, Yukun
Liao, Yiqian
Zheng, Lewei
Wu, Gaosong
Minimize the extent and morbidity of axillary dissection for node-positive breast cancer patients: implementation of axillary lymph node dissection based on breast lymphatics level
title Minimize the extent and morbidity of axillary dissection for node-positive breast cancer patients: implementation of axillary lymph node dissection based on breast lymphatics level
title_full Minimize the extent and morbidity of axillary dissection for node-positive breast cancer patients: implementation of axillary lymph node dissection based on breast lymphatics level
title_fullStr Minimize the extent and morbidity of axillary dissection for node-positive breast cancer patients: implementation of axillary lymph node dissection based on breast lymphatics level
title_full_unstemmed Minimize the extent and morbidity of axillary dissection for node-positive breast cancer patients: implementation of axillary lymph node dissection based on breast lymphatics level
title_short Minimize the extent and morbidity of axillary dissection for node-positive breast cancer patients: implementation of axillary lymph node dissection based on breast lymphatics level
title_sort minimize the extent and morbidity of axillary dissection for node-positive breast cancer patients: implementation of axillary lymph node dissection based on breast lymphatics level
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7980601/
https://www.ncbi.nlm.nih.gov/pubmed/33740930
http://dx.doi.org/10.1186/s12885-021-08024-y
work_keys_str_mv AT yuanqianqian minimizetheextentandmorbidityofaxillarydissectionfornodepositivebreastcancerpatientsimplementationofaxillarylymphnodedissectionbasedonbreastlymphaticslevel
AT houjinxuan minimizetheextentandmorbidityofaxillarydissectionfornodepositivebreastcancerpatientsimplementationofaxillarylymphnodedissectionbasedonbreastlymphaticslevel
AT heyukun minimizetheextentandmorbidityofaxillarydissectionfornodepositivebreastcancerpatientsimplementationofaxillarylymphnodedissectionbasedonbreastlymphaticslevel
AT liaoyiqian minimizetheextentandmorbidityofaxillarydissectionfornodepositivebreastcancerpatientsimplementationofaxillarylymphnodedissectionbasedonbreastlymphaticslevel
AT zhenglewei minimizetheextentandmorbidityofaxillarydissectionfornodepositivebreastcancerpatientsimplementationofaxillarylymphnodedissectionbasedonbreastlymphaticslevel
AT wugaosong minimizetheextentandmorbidityofaxillarydissectionfornodepositivebreastcancerpatientsimplementationofaxillarylymphnodedissectionbasedonbreastlymphaticslevel